Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
Condition(s)
Leukemia Lymphoma
Leukemia Lymphoma
Age Group
0-9 years 10-17 years 18-26 years 27 years and older
0-9 years 10-17 years 18-26 years 27 years and older
Phase(s)
1
1
Biological
CD22 CAR
Trial Summary & Details
Ages: 1 Year to 30 Years
Condition: Follicular Lymphoma, ALL, NHL, Large Cell Lymphoma
Condition: Follicular Lymphoma, ALL, NHL, Large Cell Lymphoma
Background:
One type of cancer therapy takes blood cells from a person, changes them in a lab, then gives the cells back to the person. In this study, researchers are using an anti-CD22 gene, a virus, and an immune receptor to change the cells.
Objective:
To see if giving anti-CD22 Chimeric Antigen Receptor (CAR) cells to young people with certain cancers is safe and effective.
Eligibility:
People ages 1-30 with a leukemia or lymphoma that has not been cured by standard therapy.